The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease
- 16 October 2007
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 69 (16), 1595-1602
- https://doi.org/10.1212/01.wnl.0000277637.33328.d8
Abstract
Background: Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are the most common genetic determinant of Parkinson disease (PD) identified to date, and have been implicated in both familial and sporadic forms of the disease. The G2019S change in LRRK2 exon 41 has been associated with disease at varying frequencies in Asian, European, North American, and North African populations, and is particularly prevalent among Ashkenazi Jews. Methods: We assessed the occurrence of the LRRK2 G2019S, I2012T, I2020T, and R1441G/C/H mutations in our cohort of Jewish Israeli patients with PD, and determined the LRRK2 haplotypes in 76 G2019S-carriers detected and in 50 noncarrier Ashkenazi patients, using six microsatellite markers that span the entire gene. Results: Only the G2019S mutation was identified among our patients with PD, 14.8% in the Ashkenazi and 2.7% in the non-Ashkenazi patients, and in 26% and 10.6% of the Ashkenazi familial and apparently sporadic cases. The carrier frequencies in the Ashkenazi and non-Ashkenazi control samples were 2.4% and 0.4%. A common shared haplotype was detected in all non-Ashkenazi and half-Ashkenazi carriers and in all full-Ashkenazi carriers tested, except two. Women and patients with a positive family history of PD were significantly over-represented among the G2019S mutation carriers. Age at disease onset was similar in carriers and noncarriers. Conclusions: Our data suggest that the LRRK2 G2019S mutation plays an important role in the causality of familial and sporadic Parkinson disease (PD) in Israel and that gender affects its frequency among patients. Although testing symptomatic patients may help establish the diagnosis of PD, the value of screening asymptomatic individuals remains questionable until the penetrance and age-dependent risk of this mutation are more accurately assessed, and specific disease prevention or modifying interventions become available. GLOSSARY: LRRK2 = leucine-rich repeat kinase 2; PD = Parkinson disease.Keywords
This publication has 30 references indexed in Scilit:
- LRRK2 G2019S in Families with Parkinson Disease Who Originated from Europe and the Middle East: Evidence of Two Distinct Founding Events Beginning Two Millennia AgoAmerican Journal of Human Genetics, 2006
- Validity and Utility of a LRRK2 G2019S Mutation Test for the Diagnosis of Parkinson's DiseaseGenetic Testing, 2006
- Clinicogenetic study of mutations inLRRK2 exon 41 in Parkinson's disease patients from 18 countriesMovement Disorders, 2006
- RNASELMutation Screening and Association Study in Ashkenazi and Non-Ashkenazi Prostate Cancer PatientsCancer Epidemiology, Biomarkers & Prevention, 2006
- Lrrk2 pathogenic substitutions in Parkinson's diseaseneurogenetics, 2005
- LRRK2 Haplotype Analyses in European and North African Families with Parkinson Disease: A Common Founder for the G2019S Mutation Dating from the 13th CenturyAmerican Journal of Human Genetics, 2005
- Genetics of Parkinsonʼs diseaseCurrent Opinion in Neurology, 2005
- Clinical features of LRRK2‐associated Parkinson's disease in central NorwayAnnals of Neurology, 2005
- Clinical and positron emission tomography of Parkinson's disease caused by LRRK2Annals of Neurology, 2005
- Cloning of the Gene Containing Mutations that Cause PARK8-Linked Parkinson's DiseaseNeuron, 2004